Skip to main content

This job has expired

Translational Medicine Leader Ophthalmology

Employer
F.Hoffmann-La Roche
Location
Basel, Canton of Basel-Stadt (CH)
Salary
competitive
Closing date
May 30, 2019

Job Details

At Roche, we believe it’s urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients’ lives and we are daring in both decision and action. And we believe that good business means a better world. That is why we come to work each day. We commit ourselves to scientific rigour, unassailable ethics, and access to medical innovations for all. We do this today to build a better tomorrow.

 

At Roche pRED, our purpose is to take on these tough medical challenges, follow the science and transform it into medicines with life-changing benefits for patients. This is what we proudly dedicate ourselves to everyday.

The Ophthalmology group is recruiting Translational Medicine Leaders to lead early development projects, chiefly in the ophthalmologic disorders.

In this role you will lead early stage clinical projects through proof of mechanism and proof of concept to transform molecules into new medicines in area with high unmet medical need. This includes enabling testing of biological and clinical hypothesis, including methods for establishing target engagement, Pharmaco-dynamic responses, patient selection and stratification and measuring disease progression.

The remit includes programs from late preclinical through Phase 3 and preparation for market authorization and filing. You will develop therapeutic area biomarker strategy and contribute to therapeutic strategy of Ophthalmology and Lead biomarker subteams and be a member of clinical and project teams as applicable.

You will be accountable for molecular and imaging biomarker data in trials involving, ensuring standardization of methodologies across sites and countries, highest data QC, monitoring of sites and CROs, and protocol compliance.

 

  • Guide diagnostic biomarker development and PHC strategy
  • Design, edit, write and review protocols and study reports for experimental medicine and clinical pharmacology studies from early proof-of-concept through global Phase III
  • Work with statisticians on analysis plans involving molecular and imaging biomarker endpoints.
  • Liaise closely with cross-functional study team members, providing expert input on data review and interpretation
  • Explore and develop novel opportunities to integrate biomarker studies into late stage development
  • Publish data in top-tier journals, attend and present at international meetings

 

Who you are

A MD with a board certification in Ophthalmology is required. An expertise in imaging of retinal diseases is a clear asset for the role.

In addition, a focus on the application of Ophthalmology biomarkers in clinical development and disease understanding could be a real asset and clinical research is preferred.

Your capacity to work effectively in multidisciplinary teams, proactive attitude, problem-solving capacity and ability to work independently is required.

Collaborative experience in pharmaceutical/biotechnology industry-based research, including expert knowledge of data acquisition and analysis within large-scale multi-center trials.

Strong publication record

Excellent oral and written communication skills in English are required

 

Are you ready to apply? We are looking a person who thinks beyond the job offered - someone who knows that this position can be a rare springboard to many other opportunities at Roche.

Roche embraces diversity and equal opportunity in a serious way. We are committed to building a team that represents a range of backgrounds, perspectives, and skills. The more inclusive we are, the better our work will be.

If you have questions then please check our FAQs and videos on careers.roche.ch/faq.

 

Roche is an equal opportunity employer.

Company

About Roche


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert